Nerve Repair and Regeneration Market Forecasts to 2030 – Global Analysis By Product (Biomaterials, Neurostimulation and Neuromodulation Devices and Other Products), Surgery (Neuromodulation Surgery, Stem Cell Therapy, Nerve Grafting and Direct Neuropathy), Application, End User and By Geography
According to Stratistics MRC, the Global Nerve Repair and Regeneration Market is accounted for $8.94 billion in 2023 and is expected to reach $22.52 billion by 2030 growing at a CAGR of 14.1% during the forecast period. Neurostimulation, neuromodulators, and biomaterial devices are among the products available for nerve repair and regeneration. These devices are used to treat traumatic or neurodegenerative diseases such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, and multiple system atrophy. Because the brain, spinal cord, and peripheral nerves are delicate and readily damaged, they can impair the brain's capacity to communicate with muscles and organs. These damages are repaired by nerve repair and regeneration products.
According to the journal The Lancet Global Health published in July 2021, it was reported that around 50 million people suffer from epilepsy, globally. As per the same source, it was also reported that around 10-12 million people are diagnosed with epilepsy, in India.
Market DynamicsDriverGlobally developing nations
Developing countries such as India, China, and Brazil are likely to provide market participants with substantial growth prospects over the projection period. The massive population base, particularly in India and China, is projected to be a big draw for enterprises approaching this market. This is aided by the increasing prevalence of neurological illnesses such as Alzheimer's, Parkinson's, and epilepsy. According to the World Bank, healthcare expenditure in these nations is increasing, which is supporting the rise of hospitals and ambulatory surgery facilities. As hospitals and ambulatory surgery centers are key end consumers of nerve repair and regeneration products, this is considered a good indicator for market expansion.
RestraintUncertain clinical outcomes
Despite significant advances in neuropathophysiology and experimental indications of promising neurotherapies, obtaining clinical outcomes in cases of avulsion, crush, or blast injuries to peripheral nerves remains difficult. Although vigorous rehabilitation after a nerve injury may reduce the incidence of muscular disuse atrophy after a nerve transaction or trauma, denervation atrophy of muscle targets is a serious impediment to nerve regeneration initiatives. Even the best neuroregeneration outcomes can be harmed by the absence of a viable neuromuscular junction (NMJ) or muscle target, resulting in poor functional outcomes.
OpportunityGrowth of geriatric population
The world's developed regions have witnessed a growth in the geriatric population. Neurologic illnesses such as stroke, neuropathy, Alzheimer's disease, and Parkinson's disease are more prevalent among the elderly population. Geriatrics make up a significant portion of the entire patient pool due to their higher susceptibility. As a result, the sustained and increased need for nerve repair and regeneration for the treatment of neurological illnesses will be ensured by the rise of this segment of the population.
ThreatNeurostimulation and neuromodulation devices are expensive
The use of neuromodulation devices has a substantial upfront cost. Because of the high cost of these devices, they may be used disproportionately in geographical locations with varying levels of financial resources. While neurostimulation has a high up-front cost for patients and insurance companies, the costs to the nation's healthcare system from long-term concerns with the treatment are insignificant. Furthermore, insurance companies cover some but not all therapy. This has an impact on the hospital's overall budget. As a result, this element would have a considerable impact on the market.
Covid-19 ImpactThe COVID-19 epidemic had a detrimental influence on the nerve repair and regeneration market because hospital and healthcare services were drastically limited due to social distancing measures implemented by governments worldwide. Furthermore, the COVID-19 pandemic had a significant impact on the functioning of general hospital treatment for non-COVID-19 patients in hospitals around the world. The need for nerve repair and regeneration procedures is decreasing as many hospitals and clinics remain closed due to the lockdown.
The stem cell therapy segment is expected to be the largest during the forecast period
Because of the increasing frequency of neurological illnesses as well as the growing desire for effective treatment alternatives, different government efforts, and approvals to perform research investigations of biomaterials, the Stem Cell Therapy segment is poised to hold the largest share throughout the projection period. Additionally, following differentiation, stem cells could be used to treat neurodegenerative illnesses by replacing defective, dead, or dying brain cells.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospital segment commanded the highest CAGR throughout the projected period. The rising frequency of neurological illnesses, the increasing number of hospitals in developing countries, and the growth and development of neuroepidemiology have all been important driving factors in the hospital segment's rise. However, continuous monitoring is an outstanding approach that assists medical and nursing staff by providing more information about the patient's physiologic condition. As hospitals are the primary end-users of nerve repair and regeneration products, this is considered a favorable indicator for market growth.
Region with largest shareDuring the forecast period, North America dominated the nerve repair and regeneration market share, owing to an increase in the prevalence of neurodegenerative and neurodevelopmental diseases, stroke, and traumatic brain injuries; an increase in the adoption of advanced healthcare infrastructure; and an increase in patient awareness of nerve repair and regeneration modalities. Furthermore, the presence of significant market competitors and frequent product developments in this area are projected to play an important role in market growth.
Region with highest CAGRDue to increased patient awareness, supportive government initiatives, the prevalence of unmet medical requirements, and the emergence of novel technologies, Asia-Pacific is expected to have the highest CAGR throughout the forecast period. Economic growth in this region's countries, the rising frequency of neurologic illnesses, the rising standard of living, the rising demand for outstanding medical care, and rising healthcare spending will drive the region's market throughout the projection period. Moreover, China, India, Japan, Australia, and Singapore are the primary contributors to the region's growth.
Key players in the marketSome of the key players in Nerve Repair and Regeneration market include Polyganics , Nevro Corp., Soterix Medical, Inc., Kerimedical, Livanova, Plc., Integra Lifesciences, Collagen Matrix, Inc., Axogen, Inc., Neuropace, Inc., Aleva Neurotherapeutics, Boston Scientific Corporation, Baxter International, Inc., Synapse Biomedical, Inc., Medtronic, Plc. and Abbott Laboratories.
Key DevelopmentsIn October 2022, Phageneis received United States FDA de novo approval for the Phagenyx neurostimulation system, which uses pharyngeal electrical stimulation to restore swallowing control in patients with severe dysphagia post-stroke.
In August 2022, Abbott received United States FDA approval for the ProClaim plus spinal cord stimulation system featuring FlexBurst therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst 360 therapy, offers pain coverage across six areas of the trunk and limbs.
Products Covered
• Biomaterials
• Neurostimulation and Neuromodulation Devices
• Other Products
Surgeries Covered
• Neuromodulation Surgery
• Stem Cell Therapy
• Nerve Grafting
• Direct Neuropathy
Applications Covered
• Nerve Grafting
• Neurostimulation and Neuromodulation Surgeries
• Stem Cell Therapy
• Direct Nerve Repair/Neurorrhaphy
• Nerve Repair & Regeneration Biomaterials
• Other Applications
End Users Covered
• Ambulatory Surgery Centers
• Clinics
• Hospitals
• Other End Users
Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances